Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting

A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study

Dual Antiplatelet Therapy (DAPT) Study Investigators

    Research output: Contribution to journal › Article

    14 Citations (Scopus)

    Abstract

    Importance: Early cardiovascular and bleeding events after coronary stenting are associated with high risk of morbidity and mortality. Objective: To assess the prognosis of cardiovascular and bleeding events occurring beyond 1 year after coronary stenting. Design, Setting, and Participants: This secondary analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multi center trial involving 220 US and in ternational clinical sites from 11 countries. The study dateswere August 2009 to May 2014. Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months. Individuals were then followed up for 3 additional months while receiving aspirin therapy alone. The analysis began in August 2015. Exposures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification moderate or severe bleeding). Main Outcomes and Measures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (GUSTO classification moderate or severe bleeding). Death at 21 months after randomization (33 months after coronary stenting). Results: Intotal, 25 682 individuals older than 18 years with an indication for coronarystentingwere enrolled, and 11 648(meanage,61.3 years; 25.1%female)were randomized. After randomization, 478 individuals (4.1%) had 502 ischemic events (306 with myocardial infarction, 113 with stent thrombosis, and 83 with ischemic stroke), and 232 individuals (2.0%) had 235 bleeding events (155 with moderate and 80 with severe bleeding). Among individuals with ischemic events, 52(10.9%) died. The annualized mortality rate after an ischemic event was 27.2 (95%CI, 20.3-35.7) per 100 person-years. The cumulative incidence of death after an ischemic event among the total randomized study population was 0.5%(0.3% with myocardial infarction,0.1% with stent thrombosis, and 0.1% with ischemic stroke). Among individuals with bleeding events, 41 (17.7%) died. The annualized mortality rate after a bleeding event was 21.5 (95%CI, 15.4-29.1) per 100 person-years. The cumulative incidence of death after a bleeding event among the total randomized study population was 0.3%(0.1% with moderate and 0.2% with severe bleeding). Conclusions and Relevance: In patients treated with dual antiplatelet therapy for at least 1 year after coronary stenting, ischemic events were more frequent than bleeding events, and both events were associated with high risk of mortality.

    Original languageEnglish (US)
    Pages (from-to)478-487
    Number of pages10
    JournalJAMA Cardiology
    Volume2
    Issue number5
    DOIs
    StatePublished - May 1 2017

    Fingerprint

    Hemorrhage
    Mortality
    Stents
    Thrombosis
    Therapeutics
    Stroke
    Myocardial Infarction
    Aspirin
    Random Allocation
    Streptokinase
    Incidence
    Tissue Plasminogen Activator
    Population
    Arteries
    Placebos
    Outcome Assessment (Health Care)
    Morbidity

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting : A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study. / Dual Antiplatelet Therapy (DAPT) Study Investigators.

    In: JAMA Cardiology, Vol. 2, No. 5, 01.05.2017, p. 478-487.

    Research output: Contribution to journal › Article

    Dual Antiplatelet Therapy (DAPT) Study Investigators 2017, 'Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting: A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study', JAMA Cardiology, vol. 2, no. 5, pp. 478-487. https://doi.org/10.1001/jamacardio.2017.0063
    Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting: A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiology. 2017 May 1;2(5):478-487. https://doi.org/10.1001/jamacardio.2017.0063
    Dual Antiplatelet Therapy (DAPT) Study Investigators. / Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting : A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study. In: JAMA Cardiology. 2017 ; Vol. 2, No. 5. pp. 478-487.
    @article{b8c1d49a085147d7ad9158c2a853bac1,
    title = "Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting: A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study",
    abstract = "Importance: Early cardiovascular and bleeding events after coronary stenting are associated with high risk of morbidity and mortality. Objective: To assess the prognosis of cardiovascular and bleeding events occurring beyond 1 year after coronary stenting. Design, Setting, and Participants: This secondary analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multi center trial involving 220 US and in ternational clinical sites from 11 countries. The study dateswere August 2009 to May 2014. Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months. Individuals were then followed up for 3 additional months while receiving aspirin therapy alone. The analysis began in August 2015. Exposures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification moderate or severe bleeding). Main Outcomes and Measures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (GUSTO classification moderate or severe bleeding). Death at 21 months after randomization (33 months after coronary stenting). Results: Intotal, 25 682 individuals older than 18 years with an indication for coronarystentingwere enrolled, and 11 648(meanage,61.3 years; 25.1{\%}female)were randomized. After randomization, 478 individuals (4.1{\%}) had 502 ischemic events (306 with myocardial infarction, 113 with stent thrombosis, and 83 with ischemic stroke), and 232 individuals (2.0{\%}) had 235 bleeding events (155 with moderate and 80 with severe bleeding). Among individuals with ischemic events, 52(10.9{\%}) died. The annualized mortality rate after an ischemic event was 27.2 (95{\%}CI, 20.3-35.7) per 100 person-years. The cumulative incidence of death after an ischemic event among the total randomized study population was 0.5{\%}(0.3{\%} with myocardial infarction,0.1{\%} with stent thrombosis, and 0.1{\%} with ischemic stroke). Among individuals with bleeding events, 41 (17.7{\%}) died. The annualized mortality rate after a bleeding event was 21.5 (95{\%}CI, 15.4-29.1) per 100 person-years. The cumulative incidence of death after a bleeding event among the total randomized study population was 0.3{\%}(0.1{\%} with moderate and 0.2{\%} with severe bleeding). Conclusions and Relevance: In patients treated with dual antiplatelet therapy for at least 1 year after coronary stenting, ischemic events were more frequent than bleeding events, and both events were associated with high risk of mortality.",
    author = "{Dual Antiplatelet Therapy (DAPT) Study Investigators} and Secemsky, {Eric A.} and Yeh, {Robert W.} and Kereiakes, {Dean J.} and Cutlip, {Donald E.} and Cohen, {David J.} and Steg, {P. Gabriel} and Cannon, {Christopher P.} and Apruzzese, {Patricia K.} and D'Agostino, {Ralph B.} and Massaro, {Joseph M.} and Laura Mauri and Aaron Kaplan and Abdel Ahmed and Ahmed, {Abdel Hamid} and Abdulhay Albirini and Abel Moreyra and Abram Rabinowitz and Adhir Shroff and Alan Moak and Alice Jacobs and Ameer Kabour and Amit Gupta and Anand Irimpen and Andrew Rosenthal and Andrew Taussig and Angelo Ferraro and Anil Chhabra and Anthony Pucillo and Anthony Spaedy and Anthony White and Antonis Pratsos and Arif Shakir and Arnold Ghitis and Arvind Agarwal and Ash Jain and Atul Chawla and Aylmer Tang and Barbara Barker and Barry Bertolet and Barry Uretsky and Bernard Erickson and Bhola Rama and Brent McLaurin and Brian Dearing and Brian Negus and Brian Price and Brigitta Brott and Brijesh Bhambi and Bruce Bowers and Saurabh Gupta",
    year = "2017",
    month = "5",
    day = "1",
    doi = "10.1001/jamacardio.2017.0063",
    language = "English (US)",
    volume = "2",
    pages = "478--487",
    journal = "JAMA Cardiology",
    issn = "2380-6583",
    publisher = "American Medical Association",
    number = "5",

    }

    TY - JOUR

    T1 - Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting

    T2 - A secondary analysis of the Dual Antiplatelet Therapy (DAPT) Study

    AU - Dual Antiplatelet Therapy (DAPT) Study Investigators

    AU - Secemsky, Eric A.

    AU - Yeh, Robert W.

    AU - Kereiakes, Dean J.

    AU - Cutlip, Donald E.

    AU - Cohen, David J.

    AU - Steg, P. Gabriel

    AU - Cannon, Christopher P.

    AU - Apruzzese, Patricia K.

    AU - D'Agostino, Ralph B.

    AU - Massaro, Joseph M.

    AU - Mauri, Laura

    AU - Kaplan, Aaron

    AU - Ahmed, Abdel

    AU - Ahmed, Abdel Hamid

    AU - Albirini, Abdulhay

    AU - Moreyra, Abel

    AU - Rabinowitz, Abram

    AU - Shroff, Adhir

    AU - Moak, Alan

    AU - Jacobs, Alice

    AU - Kabour, Ameer

    AU - Gupta, Amit

    AU - Irimpen, Anand

    AU - Rosenthal, Andrew

    AU - Taussig, Andrew

    AU - Ferraro, Angelo

    AU - Chhabra, Anil

    AU - Pucillo, Anthony

    AU - Spaedy, Anthony

    AU - White, Anthony

    AU - Pratsos, Antonis

    AU - Shakir, Arif

    AU - Ghitis, Arnold

    AU - Agarwal, Arvind

    AU - Jain, Ash

    AU - Chawla, Atul

    AU - Tang, Aylmer

    AU - Barker, Barbara

    AU - Bertolet, Barry

    AU - Uretsky, Barry

    AU - Erickson, Bernard

    AU - Rama, Bhola

    AU - McLaurin, Brent

    AU - Dearing, Brian

    AU - Negus, Brian

    AU - Price, Brian

    AU - Brott, Brigitta

    AU - Bhambi, Brijesh

    AU - Bowers, Bruce

    AU - Gupta, Saurabh

    PY - 2017/5/1

    Y1 - 2017/5/1

    N2 - Importance: Early cardiovascular and bleeding events after coronary stenting are associated with high risk of morbidity and mortality. Objective: To assess the prognosis of cardiovascular and bleeding events occurring beyond 1 year after coronary stenting. Design, Setting, and Participants: This secondary analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multi center trial involving 220 US and in ternational clinical sites from 11 countries. The study dateswere August 2009 to May 2014. Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months. Individuals were then followed up for 3 additional months while receiving aspirin therapy alone. The analysis began in August 2015. Exposures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification moderate or severe bleeding). Main Outcomes and Measures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (GUSTO classification moderate or severe bleeding). Death at 21 months after randomization (33 months after coronary stenting). Results: Intotal, 25 682 individuals older than 18 years with an indication for coronarystentingwere enrolled, and 11 648(meanage,61.3 years; 25.1%female)were randomized. After randomization, 478 individuals (4.1%) had 502 ischemic events (306 with myocardial infarction, 113 with stent thrombosis, and 83 with ischemic stroke), and 232 individuals (2.0%) had 235 bleeding events (155 with moderate and 80 with severe bleeding). Among individuals with ischemic events, 52(10.9%) died. The annualized mortality rate after an ischemic event was 27.2 (95%CI, 20.3-35.7) per 100 person-years. The cumulative incidence of death after an ischemic event among the total randomized study population was 0.5%(0.3% with myocardial infarction,0.1% with stent thrombosis, and 0.1% with ischemic stroke). Among individuals with bleeding events, 41 (17.7%) died. The annualized mortality rate after a bleeding event was 21.5 (95%CI, 15.4-29.1) per 100 person-years. The cumulative incidence of death after a bleeding event among the total randomized study population was 0.3%(0.1% with moderate and 0.2% with severe bleeding). Conclusions and Relevance: In patients treated with dual antiplatelet therapy for at least 1 year after coronary stenting, ischemic events were more frequent than bleeding events, and both events were associated with high risk of mortality.

    AB - Importance: Early cardiovascular and bleeding events after coronary stenting are associated with high risk of morbidity and mortality. Objective: To assess the prognosis of cardiovascular and bleeding events occurring beyond 1 year after coronary stenting. Design, Setting, and Participants: This secondary analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multi center trial involving 220 US and in ternational clinical sites from 11 countries. The study dateswere August 2009 to May 2014. Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months. Individuals were then followed up for 3 additional months while receiving aspirin therapy alone. The analysis began in August 2015. Exposures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification moderate or severe bleeding). Main Outcomes and Measures: Ischemic events (myocardial infarction not related to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (GUSTO classification moderate or severe bleeding). Death at 21 months after randomization (33 months after coronary stenting). Results: Intotal, 25 682 individuals older than 18 years with an indication for coronarystentingwere enrolled, and 11 648(meanage,61.3 years; 25.1%female)were randomized. After randomization, 478 individuals (4.1%) had 502 ischemic events (306 with myocardial infarction, 113 with stent thrombosis, and 83 with ischemic stroke), and 232 individuals (2.0%) had 235 bleeding events (155 with moderate and 80 with severe bleeding). Among individuals with ischemic events, 52(10.9%) died. The annualized mortality rate after an ischemic event was 27.2 (95%CI, 20.3-35.7) per 100 person-years. The cumulative incidence of death after an ischemic event among the total randomized study population was 0.5%(0.3% with myocardial infarction,0.1% with stent thrombosis, and 0.1% with ischemic stroke). Among individuals with bleeding events, 41 (17.7%) died. The annualized mortality rate after a bleeding event was 21.5 (95%CI, 15.4-29.1) per 100 person-years. The cumulative incidence of death after a bleeding event among the total randomized study population was 0.3%(0.1% with moderate and 0.2% with severe bleeding). Conclusions and Relevance: In patients treated with dual antiplatelet therapy for at least 1 year after coronary stenting, ischemic events were more frequent than bleeding events, and both events were associated with high risk of mortality.

    UR - http://www.scopus.com/inward/record.url?scp=85024386820&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85024386820&partnerID=8YFLogxK

    U2 - 10.1001/jamacardio.2017.0063

    DO - 10.1001/jamacardio.2017.0063

    M3 - Article

    VL - 2

    SP - 478

    EP - 487

    JO - JAMA Cardiology

    JF - JAMA Cardiology

    SN - 2380-6583

    IS - 5

    ER -

    Access to Document